HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Alpa Laboratories Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 14 filings·Updated 13 Aug 2026
Showing 10 of 14 filings.
13 Aug 20261 filing
ResultFinancial Results

Alpa Laboratories posts Q1 FY27 standalone revenue 2,393.05 lacs; PAT 103.84 lacs; consolidated PAT 98.04 lacs.

Financials (Standalone & Consolidated)

  • Standalone revenue from operations: 2,393.05 lacs; total income: 2,975.98 lacs.
  • Standalone PAT: 103.84 lacs; basic EPS: 0.52.
  • Consolidated revenue from operations: 2,969.35 lacs; Consolidated PAT: 98.04 lacs.

Board actions & AGM

  • Board approved unaudited standalone and consolidated results for quarter ended 30 Jun 2026.
  • Board approved notice of 38th AGM.

Operations & Compliance

  • Company operates in a single segment: Drugs & Chemicals.
  • Independent auditors issued unmodified review on both standalone and consolidated results.
Filed 20:29View Source
11 Aug 20261 filing
Company UpdateGeneral

Alpa Laboratories clarifies board meeting date as 13 August 2026; 14 August was a typographical error

Board meeting date

  • Correct date is 13 August 2026 at 3:00 PM; 14 August was a typographical error.
Filed 17:57View Source
29 Jul 20261 filing
Company UpdateGeneral

Alpa Laboratories approves in-principle plan to explore Nigeria-based entity Alpa Biopharm Limited with Blueseal

Proposed Nigeria venture

  • Approval in principle to explore establishing an overseas Nigerian entity named Alpa Biopharm Limited with Blueseal.
  • Not yet incorporated; no investment or ownership details disclosed; terms to be determined subject to regulatory approvals.
  • Proposed activities include pharmaceutical and healthcare-related business.
Filed 18:09View Source
27 Jul 20261 filing
Company UpdateReply to Clarification- Financial results

Alpa Laboratories Limited files 23-Jul-2026 submission for period ended 31-Mar-2026 with revised XBRL e-filing

Filing Status

  • Submission date 23-Jul-2026 for Alpa Laboratories Limited.
  • Period ended 31-Mar-2026; Regulation 33(3) Integrated Ind AS; revised XBRL e-filing.
Filed 13:27View Source
8 Jul 20261 filing
Company UpdateResignation of Company Secretary / Compliance Officer

Ms.Yashoda Patidar has resigned from the post of Company Secretary & Complaince Officer w.e.f. 26th July 2026.

Filed 16:35View Source
20 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

The trading Window of the company shall remain closed w.e.f, 01st April 2026 till 48 hours after the declaration of the Financial results by the company for the fourth quarter and financial ....

Filed 16:36View Source
9 Mar 20262 filings
Company UpdateGeneral

The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vinit Shah

Filed 10:23View Source
Insider Trading / SASTDisclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vinit Shah

Filed 10:17View Source
25 Feb 20261 filing
Company UpdateResignation of Company Secretary / Compliance Officer

Ms Srashti Chopra has resigned from the post of Company Secreatary and Compliance Officer wef 25th March 2026.

Filed 18:50View Source
11 Feb 20261 filing
ResultFinancial Results

Alpa Laboratories Ltd - 532878 - Alpa Laboratories Limited Has Submitted To The Exchange, The Financial Results For The Period Ended December 31, 2025.

Financial Performance 📊

  • Standalone Q3 FY26 revenue from operations: Rs 2,967.12 lakh, +16.3% YoY from Rs 2,615.02 lakh in Q3 FY25.
  • Standalone Q3 FY26 total income: Rs 2,993.17 lakh; total expenses: Rs 2,821.27 lakh.
  • Standalone Q3 FY26 profit before tax: Rs 171.89 lakh; profit after tax: Rs 187.48 lakh; EPS: Rs 0.89 (basic and diluted).
  • Nine months ended Dec 2025 standalone revenue: Rs 7,441.40 lakh; profit after tax: Rs 1,375.20 lakh; EPS: Rs 6.54.
  • Consolidated Q3 FY26 revenue from operations: Rs 2,904.58 lakh; total income: Rs 2,995.68 lakh.
  • Consolidated Q3 FY26 profit before tax: Rs 174.70 lakh; profit after tax: Rs 190.29 lakh; EPS: Rs 0.90.

Business Model & Segments

  • Company operates in a single segment: Drugs & Chemicals.
Filed 12:41View Source
Showing 10 of 14 filings